Tag: street

GREENVILLE, S.C., July 24, 2025 /PRNewswire/ -- Sola Salons, the premier salon suites concept for established salon professionals, is excited to announce its newest...

SHEIN is kicking off the season with its first Summer of Sport campaign, helping Canadians stay active and stylish with performance-driven pieces

Hey, fabulous friends! If you’re ready to chat about some serious tech magic that’s set to redefine how we roll with our investments, let’s...

LGI Homes is proud to announce the debut of five brand-new townhome floor plans at Cottonwood Greens, located northeast of Denver in Fort Lupton.

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

Studio will support startups applying artificial intelligence (AI) to real-world challenges across New York City's transportation network NEW YORK, July 23, 2025 /PRNewswire/ -- Newlab and...

Holidays at the Disneyland Resort will celebrate tradition and wonder with a flurry of returning festivities Entertainment will coincide with elements from the Disneyland Resort...

Expands global leadership team; appoints Christopher Merrill, Global CEO

Expands global leadership team; appoints Christopher Merrill, Global CEO

Hey lovely ladies, let’s dive into the world of Amazon and see if it’s a good time to grab some of those shiny stocks...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.